Is transhumanism really the world’s most dangerous idea?
By Michael Cook,
Mercatornet
| 07. 20. 2016
In 2004 the editors of the journal Foreign Policy asked several prominent intellectuals to identify the world’s most dangerous idea. Surprisingly political scientist Francis Fukuyama’s choice was transhumanism. He described it as a movement “to liberate the human race from its biological constraints”. Its supporters, he said, want to “wrest their biological destiny from evolution's blind process of random variation and adaptation and move to the next stage as a species”.
Most people would ask, “Are you kidding?” In fact, the transhumanist projects which surface in the media do sound improbable, not to say loopy. Here are three which have been widely reported.
- Elon Musk, the American billionaire boss of Tesla and Space X, recently told a conference of programmers in San Francisco that humans need to augment their brain power with “neural lace”, a fine mesh integrated into the brain which would link the brain directly to the internet. If we fail to keep pace with artificial intelligence, we will become house pets for “ultra-intelligent AI”, he said. “I don’t love the idea of being a house cat,” he...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...